Myriad RBM Management
Myriad RBM is a wholly owned subsidiary of Myriad Genetics of Salt Lake City, UT.
To see the Myriad Genetics Management Team please click here.
T. Craig Benson | President
Craig Benson joined Rules-Based Medicine, Inc. in January 2002 to direct its spin-off from Luminex Corporation. Until 2004, Benson also served as Chairman of the Board for Equity Resource Partners, LLC, a private investment company. From 1987 through September 2000, he was employed by Service Corporation International (NYSE: SCI), the world leader in death care-related services. During his tenure with SCI, he held various senior executive management positions, which included domestic and international merger and acquisition responsibilities, Vice-President of Marketing and Corporate Alliances, as well as President of SCI International, Ltd., SCI’s International holding company. From 1990 to 1994, Benson served as President of Investment Capital Corporation, the private equity arm of SCI, which held over $350 million in assets. From 1984 to 1987, he held management positions with Pulaski Investment Corporation, a private holding company engaged in commercial and mortgage banking activities. Benson has served on the Board of Directors of various publicly held entities, including Florafax International, Tanknology Environmental, Inc., Equity Corporation International and Pinnacle Global Group, Inc. He received a BBA degree from Southern Methodist University in 1984.
Michael Spain, M.D. | Chief Medical Officer
Dr. Spain joined RBM in January 2004 as Chief Medical Officer from Luminex Corporation, where he served as Vice President, Clinical Affairs and Chief Medical Officer from March 1997. From 1994 until joining Luminex, he served as Medical Director of Laboratory Corporation of America. From 1984 to 1994, he served as Medical Director of Quest Laboratory (formerly Damon Clinical Laboratory). Following a four-year residency in pathology at Baylor University Medical Center in Dallas, he became board certified in 1984. Dr. Spain received his M.D. from the University of Texas Southwestern Medical School in Dallas in 1980.
James P. Mapes, Ph.D. | Chief Scientific Officer
Dr. Mapes brings more than 15 years experience in the development and commercialization of diagnostic assay kits to Myriad RBM. Before joining Myriad RBM, Dr. Mapes was Director of Research and Development for Luminex Corporation. Prior to Luminex, he worked for Becton Dickinson as Director of Clinical Affairs, where he was responsible for biological and clinical evaluation of new products. Previously, he was with Bayer Diagnostics, EnSys Corporation and Becton Dickinson with increasing responsibilities in research and development management. After post-doctoral training at Oxford University, Oxford, England, and Texas A&M University, he held a faculty position in the Biochemistry Department at Louisiana State University Medical Center in New Orleans. Dr. Mapes received his Ph.D. in Biochemistry at Indiana University in 1975.
Ralph L. McDade, Ph.D. | Strategic Development Officer
Ralph L. McDade is the Strategic Development Officer for Myriad RBM and has held this post since the company’s inception in 2002. He was formerly the Chief Scientific Officer for Luminex Corporation from 1996-2002 where he was closely involved with the development of xMAP technology. In addition, during this period Dr. McDade was instrumental in securing technology licensing agreements with over 20 strategic partners. He received his Ph.D. in Microbiology from the University of Texas Southwestern Medical School in 1980. Following post-doctoral training at The University of Connecticut Medical Center in Farmington, he held faculty positions at the Rockefeller University in New York and at Louisiana State University School of Medicine in New Orleans.
Samuel T. LaBrie, Ph.D. | Vice President of Corporate Development
Dr. LaBrie joined RBM in May 2007. He previously served as Senior Manager of Business Development for Sigma-Aldrich, where he was responsible for strategic reviews, licensing, acquisition, and equity investment projects. Dr. LaBrie led the Sigma investments in Cyntellect and Panomics. He was the Chief Scientific Officer and Co-Founder of an antibody microarray company, ProteoPlex, which was acquired by EMD Biosciences. From 1996 to 2001, he worked for Incyte Genomics in various management and research positions as Incyte grew from 150 to 1,600 employees. Dr. LaBrie received his PhD in Biology from the University of California, San Diego.
Dominic Eisinger, Ph.D. | Director, Strategic Development
Dr. Eisinger joined Rules-Based Medicine in 2006 as part of the business development management team. Prior to Myriad RBM, he was President and Director of Business Development at Multiplex Biosciences, a multiplex immunoassay development, validation and manufacturing services company he co-founded with Dr. Laurie Stephen. A noted international authority on immunoassay, he also started and directed Upstate Cell Signaling Solutions’ multiplex business unit from its inception in 2000 until 2006.
Manfred W. Schmolz, Ph.D. | Managing Director and Chief Scientific Officer of EDI GmbH
Dr. Schmolz founded EDI GmbH in 1996 in Reutlingen, Germany. He provides Myriad RBM with expertise based on more than 20 years of experience in the development of innovative cell culture assay to characterise drug effects on the human immune system. While at EDI, he designed a series of highly complex Human Organo-Typic cell culture models (patent pending) for improved drug activity profiling. Before starting EDI, Dr. Schmolz was the head of an immunopharmacological lab he established at Bionorica GmbH. He previously served as head of quality assurance for two different manufacturers of in vitro diagnostics. Dr. Schmolz received his Ph.D. in Biology/Immunology at the Eberhard-Karls-University of Tübingen in 1987.
Laurie Stephen, Ph.D. | Director, Assay Development
Dr. Stephen joined RBM in 2006 where she is responsible for assay development and multiplexing. Prior to RBM, Dr. Stephen was Vice President and Director of Scientific Operations of Multiplex Biosciences. She managed Upstate Cell Signaling Solutions multiplex line of products and services from its inception in 2000 until 2006, including launching the first commercial kits for the Luminex® xMAP technology platform.
Margaret Sandefur, Ph.D. | Vice-President, Quality Assurance and Regulatory Compliance
Margaret Sandefur, Ph.D., Vice-President, Quality Assurance and Regulatory Compliance has been involved in Quality Assurance since the inception of Rules-Based Medicine. Dr. Sandefur has been responsible for the implementation of RBM’s Quality Programs for both CLIA and GLP. She is active in the Society of Quality Assurance (SQA) and is a Registered Quality Assurance Professional in Good Laboratory Practice (RQAP-GLP). Prior to her position at Myriad RBM, she served as Manager of Protein Chemistry at Luminex Corporation. Previously she worked in Development and Manufacturing of FDA 510k commercial control materials and point of care diagnostic materials at Abacus Diagnostic Systems and quality control and protein purification at QualiChem, LLC. Dr. Sandefur has a Ph.D. in Biochemistry from the University of Texas Health Science Center at San Antonio.
Dennis Denton | Director of Automation
Dennis Denton is the Director of Automation for Myriad RBM and has held this position since the company’s inception. He brings more than 20 years experience of software development, systems engineering and project management to the company. He held the same position for Luminex Corporation prior to joining RBM. He was a lead engineer for Luminex Corporation from its inception where he played an integral role in developing the company’s line of medical instruments and software. He received a BS degree in Computer Science from Texas A&M University in 1984.
Joshua L. Kemp | Director, Research and Development
Joshua L. Kemp joined Rules-Based Medicine in 2002 and serves as Director of Research and Development. He is responsible for the operation and supervision of the laboratory and has an integral role in directing and coordinating the development and validation of RBM Multi-Analyte Profiles. Prior to joining RBM, he served as Manager of Research and Development at Luminex Corporation and was involved in the development, optimization, and transfer of new bead-based surface chemistries from research to manufacturing. Mr. Kemp received his M.S. in Microbiology from Southwest Texas State University in 1996.